Theranos sold a beautiful idea: a single drop of blood from a finger prick, run through a compact device, yielding a full panel of diagnostic results. It was the kind of promise that rearranges an industry, and for a time it made Elizabeth Holmes the most celebrated young founder in American business. The problem, established later in painstaking detail, was that the technology could not deliver the results being claimed for it. This is the rare case where the popular verdict and the legal record agree.
Key facts
- Company
- Theranos, blood-testing technology
- Founder
- Elizabeth Holmes
- Regulatory action
- SEC charges in 2018
- Criminal outcome
- Convicted in 2022 on four counts of defrauding investors; sentenced to more than eleven years
- Not established
- The jury did not convict on the patient-related counts, acquitting on some and failing to reach a verdict on others
The claims
The company represented that its proprietary device could perform a wide range of tests accurately from a tiny blood sample, and it built partnerships and a soaring valuation on that representation. Behind the scenes, reporting later showed, the device could not reliably do so, and much testing was carried out on conventional commercial machines. The gap between the public claim and the operational reality was the heart of everything that followed.
The exposure
The turn came through investigative journalism, most prominently a series of reports in the Wall Street Journal that questioned whether the technology worked as advertised and described the company's reliance on standard analysers. Regulatory scrutiny of the company's laboratory operations followed. The narrative that had carried Theranos upward reversed, and the company that had been a symbol of disruption became a symbol of something else.
The findings
In 2018 the Securities and Exchange Commission brought charges, resolving its case against Holmes on terms that included financial penalties and restrictions. The criminal case came later. In early 2022, after a lengthy trial, a jury convicted Holmes on four counts related to defrauding investors, and she was subsequently sentenced to a prison term of more than eleven years. This is a finding of personal fraud to the criminal standard, the top rung of the ladder of certainty we describe in our methodology.
What was not proven
Precision cuts both ways, and honest reporting records the limits of a verdict as carefully as its substance. The jury did not convict Holmes on the counts concerning patients, acquitting on some and failing to reach a verdict on others. The convictions that stand concern the deception of investors. Noting this is not a softening of the verdict; it is a refusal to overstate it. The established crime is investor fraud, and that is severe enough to need no embellishment.
Why it is the benchmark
Theranos matters to this publication as a calibration point. When people reach for the word "fraud" to describe any startup that failed, Theranos is the standard they are implicitly invoking: a documented gap between claim and reality, a regulator, a jury, and a conviction of the individual. Most failed companies do not meet that standard, which is exactly why the ones that do deserve the word, and the ones that do not deserve a more accurate one. Compare it with our WeWork investigation, where a comparable collapse in value produced no charges at all.